Mylan Management Discusses Q2 2012 Results - Earnings Call Transcript

Mylan (MYL)

Q2 2012 Earnings Call

July 26, 2012 10:30 am ET

Executives

Kris King

Heather Bresch - Chief Executive Officer and Director

John D. Sheehan - Chief Financial Officer and Executive Vice President

Analysts

David Risinger - Morgan Stanley, Research Division

Gary Nachman - Susquehanna Financial Group, LLLP, Research Division

Frank H. Pinkerton - SunTrust Robinson Humphrey, Inc., Research Division

Marc Goodman - UBS Investment Bank, Research Division

Elliot Wilbur - Needham & Company, LLC, Research Division

Aaron Gal - Sanford C. Bernstein & Co., LLC., Research Division

Ken Cacciatore - Cowen and Company, LLC, Research Division

Shibani Malhotra - RBC Capital Markets, LLC, Research Division

Jami Rubin - Goldman Sachs Group Inc., Research Division

Presentation

Operator

Welcome to Mylan's Second Quarter Earnings Conference Call and Webcast. Hosting the call today from Mylan is Ms. Kris King, Vice President, Global Investor Relations. Today's call is being recorded and will be available for replay beginning at 1 p.m. Eastern Standard Time. The dial-in number is (800) 585-8367 or (404) 537-3406 for international callers, with pin number 94584310. [Operator Instructions] It is now my pleasure to turn the floor over to Kris King. You may begin.

Kris King

Thank you, Beverly. Good morning, everyone. Welcome to Mylan's Second Quarter 2012 Earnings Call. Joining me for today's call are Mylan's Chief Executive Officer, Heather Bresch; President, Rajiv Malik; Chief Operating Officer, Hal Korman; and Executive Vice President and Chief Financial Officer, John Sheehan.

During today's call, including the Q&A, we will be making numerous forward-looking statements pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements often may be identified with the use of words such as may, will, could, should, would, project, believe, anticipate, expect, plan, estimate, guidance, trends, forecast, potential, intend, continue and variations of these words or comparable words.

If you liked this article you might like

Allergan's Restasis Patent Transfer to Face Precedent-Setting Legal Battle

FDA Official Calls for Ending Codeine Use in Kids Cough Products

Will Allergan's Deal With Tribe Hold Up?

Trading Mylan: Look Out for This Key Level

Big Drug Makers Could Face More Pressure on Codeine Remedies for Kids